Research and licensing agreement for treatment of dyslipidemiaResearch and Licensing Agreement • July 5th, 2024
Contract Type FiledJuly 5th, 2024Ligand Pharmaceuticals has entered into a licensing agreement and research collaboration with Omthera Pharmaceuticals for the development of products to treat dyslipidemia, including hypertriglyceridemia.